Table 2 Clinical characteristics and prognosis of the KRAS-wild-type and KRAS-mutant groups

Age (years, mean, SD)

56.51 (9.62)

56.89 (9.71)

0.849

Sex (n, %)

  Female

17 (25.37)

11 (30.56)

0.573

  Male

50 (74.63)

25 (69.44)

-

Pathology (n, %)

  High

5 (7.46)

2 (5.56)

0.916

  Moderate

40 (59.70)

24 (66.67)

-

  Poor

7 (10.45)

3 (8.33)

-

  Not defined

15 (22.39)

7 (19.44)

-

Location (n, %)

  ≤5 cm

31 (46.27)

15 (41.67)

0.217

  5–10 cm

33 (49.25)

21 (58.33)

-

  >10 cm

3 (4.48)

0 (0)

-

Clinical T stage (n, %)

  cT2

1 (1.49)

2 (5.56)

0.510

  cT3

50 (74.63)

25 (69.44)

-

  cT4

16 (23.88)

9 (25.00)

-

Serum CEA (n, %)

  ＞5 ng/ml

45 (67.16)

19 (52.78)

0.151

  ≤5 ng/ml

22 (32.84)

17 (47.22)

-

Pathologic T stage (n, %)

  pT0

8 (11.94)

2 (5.56)

0.539

  pT1

3 (4.48)

1 (2.78)

  pT2

20 (29.85)

11 (30.56)

  pT3

36 (53.73)

21 (58.33)

  pT4

0 (0)

1 (2.78)

Pathologic N stage (n, %)

  pN0

37 (55.22)

22 (61.11)

0.767

  pN1

24 (35.82)

12 (33.33)

  pN2

6 (8.96)

2 (5.56)

Prognosis

  Lung metastasis (n, %)

7 (10.45)

11 (28.95)

0.010

  Liver metastasis (n, %)

5 (7.81)

3 (8.33)

0.875

  Bone metastasis (n, %)

4 (5.97)

0 (0)

0.295

  Abdominal lymph node or peritoneal metastasis (n, %)

7 (10.45)

1 (2.78)

0.256